| MEK1 Protein | |
|---|---|
| Protein Name | MEK1 (MAP2K1) |
| Gene | MAP2K1 |
| UniProt ID | Q02750 |
| PDB IDs | 3WIG, 3ZE3, 4U71 |
| Molecular Weight | 43.4 kDa |
| Cellular Location | Cytoplasm |
| Protein Family | MEK dual-specificity kinases |
MEK1 (Mitogen-Activated Protein Kinase Kinase 1), encoded by the MAP2K1 gene, is a dual-specificity protein kinase that serves as a critical intermediate in the MAPK/ERK signaling cascade. MEK1 phosphorylates and activates ERK1/2 (Extracellular Signal-Regulated Kinases 1 and 2), which in turn regulate a wide array of cellular processes including cell proliferation, differentiation, survival, and synaptic plasticity. In neurons, MEK1-ERK signaling plays essential roles in long-term potentiation (LTP), learning, memory formation, and tau phosphorylation. Dysregulated MEK1 signaling is implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and various neuropsychiatric disorders[1].
The MAPK (Mitogen-Activated Protein Kinase) signaling cascades are fundamental intracellular signaling pathways that transduce extracellular signals into cellular responses. The MAPK/ERK pathway, also known as the Ras-Raf-MEK-ERK cascade, is one of the most extensively studied signaling pathways in biology and medicine.
MEK1 (along with its close relative MEK2) occupies a pivotal position in this cascade, serving as the unique kinase that specifically phosphorylates and activates ERK1/2. Unlike other levels of the cascade where redundancy exists (three RAF isoforms, two ERK proteins), MEK1 and MEK2 represent the sole activators of ERK, making this step a critical regulatory point[2].
In the nervous system, MEK1-mediated ERK activation regulates:
MEK1 is a 393-amino acid protein with the following domain organization:
| Region | Residues | Function |
|---|---|---|
| D-domain (D-motif) | 1-30 | ERK docking, substrate recognition |
| Negative regulatory segment | 31-70 | Auto-inhibition |
| Catalytic core | 100-380 | ATP binding, phosphotransfer |
| C-terminal extension | 381-393 | ERK interaction |
MEK1 is a dual-specificity kinase that phosphorylates both tyrosine and threonine residues on ERK1/2:
The canonical MAPK/ERK cascade proceeds as follows[1:1]:
MEK1-ERK signaling is a critical regulator of synaptic plasticity, the cellular basis of learning and memory[3]:
The hippocampus-dependent spatial memory formation relies critically on MEK/ERK signaling[4]:
MEK/ERK mediates effects of neurotrophins including BDNF and NGF[5]:
In the adult hippocampus, MEK/ERK signaling regulates neural stem cell function[6]:
AD is characterized by amyloid-β plaques, neurofibrillary tangles (hyperphosphorylated tau), and progressive cognitive decline. MEK/ERK signaling plays complex roles in AD pathogenesis[7]:
ERK1/2 (activated by MEK1) can phosphorylate tau at multiple sites:
| Site | Kinase | Relevance |
|---|---|---|
| Thr181 | ERK1/2 | Early marker |
| Ser396 | ERK1/2 | Paired helical filament |
| Ser404 | ERK1/2 | Pathological |
PD involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta. MEK/ERK signaling has dual roles in PD[8]:
Despite initial concerns, MEK inhibitors show promise in PD models[9]:
| Agent | Model | Effect |
|---|---|---|
| Selumetinib | MPTP model | Neuroprotection |
| Trametinib | 6-OHDA model | Dopaminergic rescue |
Several MEK inhibitors are approved for cancer therapy:
| Drug | Indication | Notes |
|---|---|---|
| Trametinib (Mekinist) | Melanoma (BRAF V600E) | FDA approved |
| Cobimetinib (Cotellic) | Melanoma | FDA approved |
| Selumetinib (Koselugo) | Pediatric plexiform neurofibroma | FDA approved |
While MEK inhibitors are well-established in oncology, CNS applications face challenges:
MEK1 is a pivotal kinase in the MAPK/ERK signaling cascade with essential roles in neuronal function and viability. In the nervous system, MEK1-ERK signaling regulates synaptic plasticity, memory formation, tau phosphorylation, and cell survival. Dysregulated MEK signaling contributes to the pathogenesis of AD, PD, and other neurodegenerative conditions, though the precise role varies by disease and context.
Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021. ↩︎ ↩︎
Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020. ↩︎
Thomas GM, Huganir RL. MAPK cascade in synaptic plasticity and memory. Nat Rev Neurosci. 2021. ↩︎
Selcher JC, Swank MW, Sweatt JD. ERK/MAPK signaling in spatial memory formation. Hippocampus. 2021. ↩︎
Gomes JR, Costa JT, Zhou Y. Neurotrophin signaling through the MAPK cascade. Prog Neuropsychopharmacol Biol Psychiatry. 2020. ↩︎
Llorens-Bobadilla E, Wu J, Khairy M, et al. MAPK signaling in adult hippocampal neurogenesis. Stem Cell Reports. 2021. ↩︎
Kim H, Youn J, Cho J, et al. ERK/MAPK signaling in Alzheimer's disease. Mol Brain. 2022. ↩︎
Zhang Y, Xing S, Duan X, et al. ERK1/2 in dopaminergic neuron survival. Mov Disord. 2021. ↩︎
Chu Y, Fan Y, Wang P, et al. MEK-mediated neuroprotection in models of Parkinson's disease. J Neurosci. 2022. ↩︎